甲福明和大动脉动脉瘤和大动脉解剖的风险:孟德尔的随机化研究
Lei Wang1,2, Ziyan Lin3, Yuzuo Lin3
1Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, 350000 Fuzhou, Fujian, China.
Reviews in cardiovascular medicine
|May 12, 2025
概括
甲福明可以降低大动脉动脉瘤 (AA) 和大动脉剖析 (AD) 的风险. 这项门德尔的随机化研究发现,甲福明对这些严重的血管疾病有保护作用.
科学领域:
- 心血管遗传学 心血管遗传学
- 药物基因组学 药物基因组学
- 血管生物学 血管生物学
背景情况:
- 以前的研究表明,甲福明可能会抑制腹腔大动脉瘤 (AAA) 扩张,但这些发现引起争议.
- 关于甲福明与胸前大动脉动脉瘤 (TAA) 和大动脉剖析 (AD) 的关系的研究有限.
研究的目的:
- 调查甲福明使用与大动脉动脉瘤 (AA) 和大动脉解剖 (AD) 风险之间的潜在关系.
- 使用孟德尔随机化 (MR) 评估甲福林和AA/AD之间的遗传因果关系.
主要方法:
- 利用全基因组关联研究和FinnGen总结数据进行MR分析.
- 使用反变量加权 (IVW) 方法来确定因果关系.
- 进行敏感性分析以评估异质性和性.
主要成果:
- 在甲福明和AA和AD风险之间观察到显著的负相关性.
- 甲胺对AA (OR=0.010),AAA (OR=0.004),TAA (OR=0.017) 和AD (OR=0.001) 的低概率比率 (ORs) 显示出保护作用.
- 敏感性分析证实了这些发现的可靠性.
结论:
- 确定了在甲福明使用和降低AA/AD风险之间存在潜在的遗传因果关系.
- 建议甲福明可以作为一种保护剂,防止大动脉动脉瘤和剖析的发生.
相关概念视频
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...


